Welcome to our dedicated page for MOLECULAR PARTNERS SEC filings (Ticker: MOLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Molecular Partners AG's SEC filings document a foreign private issuer developing DARPin therapeutics for oncology, including targeted radiopharmaceuticals and immune-engaging protein drug candidates. Its Form 6-K reports furnish press releases, annual report materials, clinical and preclinical program updates, financial results, and scientific disclosures tied to candidates such as MP0712, MP0317, MP0533 and other DARPin programs.
The filings also cover shareholder-meeting materials, board elections, compensation votes, consolidated financial statements, and incorporation of certain Form 6-K exhibits into registration statements. Annual report disclosures describe the company's pipeline, partnerships, research and development focus, cash resources, governance framework, and public-company reporting as a Swiss issuer listed on SIX and Nasdaq.
Molecular Partners AG furnished a press release and unaudited condensed interim financials for the three and nine months ended September 30, 2025. The company reported a net loss of CHF 49,002 thousand for the nine-month period and CHF 11,836 thousand for the quarter. Revenues were nil after prior-period collaboration income ended, while operating expenses totaled CHF 45,502 thousand year-to-date, including a CHF 2,733 thousand restructuring charge tied to a June 2025 efficiency initiative.
Research and development expense was CHF 30,954 thousand and selling, general and administrative expense was CHF 11,815 thousand for the nine months. Basic and diluted net result per share was CHF (1.32) year-to-date and CHF (0.33) in the quarter. Cash and cash equivalents were CHF 82,359 thousand with short-term time deposits of CHF 22,162 thousand as of September 30, 2025. Net cash used in operating activities was CHF 40,106 thousand for the nine months, partly offset by movements in time deposits, leading to a period-end cash balance increase from January 1.
Total shareholders’ equity was CHF 95,529 thousand at quarter-end. Collaboration with Novartis ended in 2024, and the company recorded no revenue from that agreement in 2025.
Molecular Partners (MOLN) reported H1 2025 results showing continued investment in its DARPin drug platform and a solid cash runway. The company has CHF 114.5 million in cash and short-term deposits as of June 30, 2025 and expects to be funded into 2028 excluding potential partner receipts. In H1 2025 it used CHF 30.2 million in operating cash, recorded an operating loss of CHF 33.5 million and a net loss of CHF 37.2 million, and recognized CHF 2.6 million of restructuring expenses. Development highlights include a co-development with Orano Med on 212Pb Radio-DARPin candidates MP0712 (DLL3) and MP0726 (MSLN), positive preclinical MP0712 data presented at AACR 2025, ongoing FDA dialogue with an IND filing for MP0712 expected in Q3 2025 and first-in-human dosing planned in 2025 pending clearance, with initial clinical data expected in H1 2026. H1 2025 financial statements are available on the company's website.
Molecular Partners AG has filed an S-8 registration statement to register securities related to three employee benefit plans: Performance Share Plan 2025 for Employees, Performance Share Plan 2025 for Management, and Restricted Share Plan 2025.
Key details of the filing:
- Filed on June 25, 2025 for Swiss-based biotech company trading under symbol MOLN
- Registration covers three distinct employee benefit plans introduced in 2025
- Company maintains principal executive offices in Zurich-Schlieren, Switzerland with U.S. presence in Cambridge, Massachusetts
- Filing incorporates by reference the company's annual report on Form 20-F for FY2024 and recent Form 6-K reports
The registration is signed by CEO Patrick Amstutz and includes signatures from the full board of directors, including Chairman William Burns. The company has appointed legal representation from Cooley LLP (US) and Homburger AG (Switzerland) for this filing. This registration enables Molecular Partners to offer equity-based compensation to both employees and management under these newly established plans.